CROWN BIOSCIENCE

HuMark™

Discover and validate novel oncology biomarkers

A JSR Life Sciences Company

QUICKFACT

V1.0

Access 2,500 Hu**Prime**® PDX (patient-derived xenograft) *in vivo* tumor models to identify biomarkers of response.

Profile, identify, and confirm PD, surrogate, and predictive biomarkers, leveraging the power of well-characterized and annotated Hu**Prime** models.

- Large, diverse collection of 2,500 PDX models from US, European, and Asian populations covering >30 cancer types.

- Curated, online, searchable database (Hu**Base**™) of:
  - Phenotypic and genotypic data
  - Patient information
  - Growth curves
  - Standard of care treatment data

- Constantly growing panels of PDX with patient-relevant mutations

- Unique models for targeted therapy e.g. RET, ALK, EGFR

- PD biomarker studies by IHC to discover pharmacodynamic response

Differentiate between responders and non-responders in a patient population

Discover pharmacology response by IHC from *in vivo* efficacy studies

Validate targets by screening population response to drug candidates

T-c-Met, p-c-Met, and HGF in 20 lung HuPrime models